XML 225 R143.htm IDEA: XBRL DOCUMENT v3.22.4

Collaborative and Other Relationships - Summary of Activity Related to Sangamo Therapeutics (Details) - Research and development - Sangamo Therapeutics, Inc. Agreement - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2022	Dec. 31, 2021	Dec. 31, 2020
Collaborative arrangements and non-collaborative arrangement transactions
Expense incurred by the collaboration	$ 19.1	$ 22.7	$ 10.1
Expense reflected within statements of income	$ 12.1	$ 14.6	$ 6.4

X

- Definition

Expense incurred by the collaboration

+ References

No definition available.

+ Details

Name:	biib_Expenseincurredbythecollaboration
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Expense reflected within statements of income

+ References

No definition available.

+ Details

Name:	biib_Expensereflectedwithinstatementsofincome
Namespace Prefix:	biib_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

X

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

X

- Details

Name:	us-gaap_TypeOfArrangementAxis=biib_SangamoTherapeuticsIncAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type: